Optipharm.CO.,LTD: debt-to-equity, ROE and more

Latest fiscal year ratios (computed here)

Debt/equity

60.5%

Equity ratio

62.3%

ROE

-9.8%

Op. margin

-10.8%

Rev. growth

13.8%

Interest coverage

n/a

Condition flags

• Latest operating profit is not above zero, or not reported.
• Operating loss for 5 straight years.
• Total equity is above paid-in capital. Not capital-impaired.

Interest coverage and dividends (OpenDART)

Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.

Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.

Ratios by year (computed here)

• Debt-to-equity = total liabilities ÷ total equity × 100
• Equity ratio = total equity ÷ total assets × 100
• ROE = net income ÷ year-end total equity × 100
• Operating margin = operating profit ÷ revenue × 100
• Revenue growth = (this year − last year) ÷ last year × 100

Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.

Source figures (FSC summary statements)

Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.

Back to the lists

• Low debt-to-equity Korean companies
• High equity ratio Korean companies
• High ROE Korean companies
• High operating margin Korean companies
• Fastest revenue growth Korean companies
• 5 straight years of operating profit
• Capital-impaired Korean companies
• Korean companies with operating losses